New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque ...

It is more common in teenagers and young adults ... It May Heal Scalp Conditions In a study examining turmeric's effect on one skin condition, scalp psoriasis, 40 patients were divided into two groups ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.

Icotrokinra demonstrated high rates of skin clearance in patients with scalp psoriasis as 66% achieved a scalp-specific Investigator's Global Assessment (ss-IGA) c score of 0/1 compared to 11% ...

Roflumilast foam 0.3% applied once daily led to significantly greater clearance of scalp and body plaque psoriasis lesions and more rapid itch reduction than placebo over eight weeks.

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam ...

In clinical trials, roflumilast foam has shown strong potential in reducing psoriasis symptoms on both the scalp and body. Though, in this study, researchers explored roflumilast foam’s safety and ...